An Act Concerning Research And Development Tax Credits For Biotechnology Companies.
Summary
SB 736 would amend Connecticut’s tax credit statutes to provide more favorable research and development tax treatment for biotechnology companies. Specifically, it would raise the research and development tax credit exchange rate under section 12-217ee to 100% for biotechnology companies, meaning those companies could exchange qualifying credits at full value rather than at a discounted rate. It would also increase the cap under section 12-217zz so biotechnology companies could use up to 100% of their research and development credits.
In addition, the bill would create a new tax credit for research and development expenses incurred by biotechnology pass-through entities, such as partnerships and LLCs taxed through to owners. The stated purpose is to expand the availability and usefulness of R&D incentives for the biotechnology sector and to support companies engaged in research-intensive activity.
Impact
If enacted, the bill would modify Connecticut’s corporate and business tax credit rules by carving out special treatment for biotechnology companies and biotechnology pass-through entities. It would affect the administration of research and development credits under sections 12-217ee and 12-217zz of the general statutes and create a new credit mechanism for qualifying biotech pass-through entities. The practical effect would be to reduce tax liability or increase the monetization of R&D credits for eligible biotechnology businesses, potentially improving cash flow and investment incentives in that sector.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available record. Based on the bill text, the measure appears pro-industry and intended to encourage biotechnology research and development in Connecticut. The framing suggests a generally favorable policy goal of strengthening the state’s biotech sector through targeted tax incentives.
Contention
The main likely point of contention is the bill’s targeted tax preference for biotechnology companies over other industries. Supporters would likely argue that biotech research is capital-intensive and merits enhanced incentives to attract investment and jobs, while critics may question whether the state should provide a special carveout rather than broader, industry-neutral R&D relief. Another possible issue is the fiscal impact on state revenue, since increasing credit exchange and utilization limits and creating a new credit would likely reduce tax collections.